Home » Genzyme’s “Theoretical Cure” for MS Draws Scrutiny, Sanofi
Genzyme’s “Theoretical Cure” for MS Draws Scrutiny, Sanofi
Genzyme Corp.’s experimental drug for multiple sclerosis, the treatment central to negotiations in Sanofi-Aventis SA’s $20.1 billion takeover, will profit investors only if its early promise proves true in later tests.
Bloomberg
Bloomberg
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May